Combined oral upadacitinib and 308-nm excimer light for refractory progressive non-segmental vitiligo: A prospective observational study in 14 adults and 2 pediatric cases

VASI scores of 16 patients (adults and children) with progressive refractory non-segmental vitiligo treated with oral upadacitinib combined with 308-nm excimer light at 12, 16, 20, and 24 weeks.本数据集收录了16例成人及儿童进展性难治性非节段型白癜风患者的VASI（白癜风面积与严重程度指数，Vitiligo Area and Severity Index）评分数据，这些患者接受口服乌帕替尼（upadacitinib）联合308nm准分子光治疗，评估时间点为第12、16、20及24周。